Recently, the "National Proprietary Chinese Medicine Alliance Procurement Announcement (No.
1 of 2022)" document was officially released
.
In addition to Hunan, Fujian, Hong Kong, Macao and Taiwan, 30 provincial-level domestic proprietary Chinese medicine procurement offices have formed a national joint procurement office for proprietary Chinese medicines, which has collected 16 product groups and 42 proprietary Chinese medicine products
.
The industry believes that the proprietary Chinese medicine industry has always had problems such as inflated prices and speculation of medicinal materials, and the normalization of the collection of proprietary Chinese medicines will bring about a major reshuffle of the market, at the same time, proprietary Chinese medicine enterprises are also facing some new opportunities
.
On the one hand, after the collection, Chinese medicine enterprises will pay more attention to research and development, continue to increase investment in research and development, focus on the field of research and development of innovative Chinese medicine drugs with more clinical value, or tap the new uses of old products, and develop new drugs with improved Chinese medicine.
For example, Livzon Pharmaceutical said that the company is focusing on promoting the research and development progress and layout of new products such as ancient classic Chinese medicine compound new drugs, dosage form improved new drugs, and in-hospital preparations such as Chinese medicine class 1 new drugs, and the product structure of the Chinese medicine sector is expected to continue to be optimized, and the profitability level will be further improved
.
As a traditional Chinese medicine enterprise that has transformed from a traditional Chinese medicine enterprise into a high-barrier complex preparation & innovative drug enterprise based on technology platforms such as biological drugs and microspheres, the main varieties of Lizhu Pharmaceutical have undergone many iterations, and continuous R&D investment
is inseparable from it.
According to the 2022 semi-annual report, the total related expenditure on research and development in the first half of the year was 639 million yuan, an increase of 17.
22% year-on-year, and the proportion of research and development investment in revenue reached 10.
14%.
In recent years, the enthusiasm for the research and development of new Chinese medicine drugs in China has been high, and the news of approval has continued
.
Just recently, the State Food and Drug Administration approved the listing registration application of Wuhan Guanggu Renfu's Class 1.
2 Chinese Medicine Innovation Drug Guangqiancao Total Flavonoid Capsules, which is also another breakthrough
following the approval of the listing of the Class 1 Chinese medicine innovative drug "Qirui Gastrin Capsule" independently developed by Jianmin Pharmaceutical in December 2021.
For example, on February 28, Yunnan Baiyao's declaration of a new class of Chinese medicine drug "Quansanqi Tablets" was approved by the State Food and Drug Administration, and the drug will be used for clinical trials
of chest tightness and heartache caused by heart artery stasis.
According to statistics, in 2021 alone, 12 new Chinese medicine drugs have been approved, the number of which has exceeded the sum of the past 4 years, and the indications cover multiple disease fields
such as respiratory, digestive, endocrine and nervous system diseases.
The approval of a large number of new Chinese medicine drugs shows that the transformation of the industry is accelerating
.
On the other hand, the purpose of collection is to improve quality and reduce prices to benefit patients
.
For pharmaceutical companies, in the short term, although the implementation of policies such as the collection of proprietary Chinese medicines and the control of medical insurance fees will make the life of industry enterprises more difficult, the profit side is under obvious pressure, and some enterprises that do not have market competitiveness will be eliminated, but it is an opportunity
for pharmaceutical companies that take the road of modernization and innovative development of proprietary Chinese medicines.
In the long run, proprietary Chinese medicines are supported by favorable policies, including the Notice on Several Policies on Accelerating the Development of the Characteristics of Traditional Chinese Medicine, the Requirements for Registration Classification and Declaration Materials of Chinese Medicines, the Guiding Principles for Pharmaceutical Research of Compound Preparations of Chinese Medicines Managed According to the Catalogue of Ancient Classic Prescriptions (Trial), the Guiding Opinions on Medical Insurance to Support the Inheritance and Innovative Development of Traditional Chinese Medicine, and the "14th Five-Year Plan for the Development of Traditional Chinese Medicine", encouraging and supporting the innovative development of Chinese medicine enterprises, coupled with the aging of the population.
As well as consumption upgrading, consumers pay more and more attention to the concept of health, the overall demand of the industry is good, the market scale will continue to expand, and develop in the direction of
high quality and standardization.
